Cadrenal Therapeutics, Inc. (CVKD) AI Stock Analysis

• Market Cap: $12.28M
• Dividend Yield: N/A
• Average Volume (3M): 58.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: -9.80%
• Country: US
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.37
• Shares Outstanding: 2,506,817
• 10 Day Avg. Volume: 57,800
• 30 Day Avg. Volume: 58,547
• PEG Ratio: 0.00
• Price to Book (P/B): 4.94
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.07
• Enterprise Value/Market Cap: 0.61
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.26K
• Enterprise Value/Ebitda: -0.56
• 1Y Price Target: $45.00
• Price Target Upside: 248.30% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -4.21
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $5.00 ▼(-61.30% Downside)
• Action: Reiterated Date: 04/01/26
• Date: Action: Reiterated 04/01/26

The score is primarily held down by weak financial performance (no revenue, widening losses, and accelerating cash burn with declining equity) and bearish technical trends (price below all key moving averages with negative MACD). Corporate events provide some offset via near-term funding and positive preclinical updates, but dilution risk tempers the benefit; valuation signals provide limited support given the lack of meaningful earnings/dividend metrics.

Positive Factors

Pipeline differentiation — 12-LOX inhibitor

Cadrenal's CAD-1005 represents a first-in-class mechanism (12-LOX inhibition) in the HIT space, creating a durable competitive edge. A unique mechanism can support exclusivity, partnership interest and premium positioning versus incumbent anticoagulants, improving long-term commercial optionality.

Negative Factors

No revenue and widening losses

Cadrenal remains pre-revenue with growing net losses, indicating an extended reliance on external capital. Persistent negative profitability means long-term value creation depends entirely on successful clinical outcomes or partnerships; failure to achieve those would make sustained operations difficult without repeated dilution.

Cadrenal Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in...

Read more

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in...

How the Company Makes Money

null...

Cadrenal Therapeutics, Inc. Financial Statement Overview

Breakdown	Mar 2026	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	-1.88K	0.00	-1.27K
EBITDA	-13.46M	-10.65M	-8.34M	-6.61M
Net Income	0.00	-10.65M	-8.36M	-6.71M
Balance Sheet
Total Assets	4.33M	10.12M	8.52M	778.17K
Cash, Cash Equivalents and Short-Term Investments	4.01M	10.02M	8.40M	32.59K
Total Debt	0.00	0.00	21.35K	640.71K
Total Liabilities	1.59M	2.68M	826.88K	6.33M
Stockholders Equity	2.74M	7.44M	7.69M	-5.55M
Cash Flow
Free Cash Flow	-12.60M	-7.36M	-3.53M	-1.20M
Operating Cash Flow	-12.60M	-7.36M	-3.53M	-1.20M
Investing Cash Flow	-5.10K	-6.54K	-3.25K	-2.28K
Financing Cash Flow	6.60M	8.98M	11.90M	1.24M

Cadrenal Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 12.92
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Negative. The current price of 12.92 is above the 20-day moving average (MA) of 6.61, above the 50-day MA of 6.77, and above the 200-day MA of 10.33, indicating a bearish trend. The MACD of -0.68 indicates Positive momentum. The RSI at 34.35 is Neutral, neither overbought nor oversold. The STOCH value of 18.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVKD.

Cadrenal Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DARE	48 Neutral	$27.66M	-16.10	274.47%	―	―	―
CLGN	44 Neutral	$7.69M	-1.49	-92.74%	―	280.77%	32.82%
HIND	43 Neutral	$15.09M	-0.72	-364.96%	―	-48.74%	89.18%
CVKD	42 Neutral	$12.28M	―	-256.79%	―	―	-9.80%

Cadrenal Therapeutics, Inc. Corporate Events